Citalopram 10mg tablets

Land: Storbritannia

Språk: engelsk

Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktiv ingrediens:

Citalopram hydrobromide

Tilgjengelig fra:

Viatris UK Healthcare Ltd

ATC-kode:

N06AB04

INN (International Name):

Citalopram hydrobromide

Dosering :

10mg

Legemiddelform:

Oral tablet

Administreringsrute:

Oral

Klasse:

No Controlled Drug Status

Resept typen:

Valid as a prescribable product

Produkt oppsummering:

BNF: 04030300; GTIN: 5016695291741

Informasjon til brukeren

uk-pl-10mg20mguk0531-art613-clean
Page 1 of 10
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
CITALOPRAM 10 MG FILM-COATED TABLETS
CITALOPRAM 20 MG FILM-COATED TABLETS
citalopram
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
-
If you get side effects, talk to your doctor or pharmacist. This
includes any possible any side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Citalopram is and what it is used for
2.
What you need to know before you take Citalopram
3.
How to take Citalopram
4.
Possible side effects
5.
How to store Citalopram
6.
Contents of the pack and other information
1.
WHAT CITALOPRAM IS AND WHAT IT IS USED FOR
Citalopram belongs to a group of medicines called selective serotonin
reuptake inhibitors (SSRIs),
also known as antidepressants.
Citalopram is used to treat:

depression (major depressive episodes)

panic disorder (panic attacks, including those caused by agoraphobia,
which is a fear of
open spaces).
_ _
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE CITALOPRAM
DO NOT TAKE CITALOPRAM

if you are allergic to citalopram or any of the other ingredients of
this medicine (listed in
section 6).

if you are taking, or have taken within the last two weeks, any
monoamine oxidase inhibitors
(MAOIs). These medicines are used to treat depression or Parkinson’s
disease (e.g. selegiline,
moclobemide). After stopping Citalopram you must allow one week before
taking any MAOIs

if you are taking the antibiotic linezolid (unless your doctor is able
to monitor your blood
pressure)

if you are taking pimozide (to treat mental illnesses)

if you are taking sumatriptan (5-HT agonist) used to treat migraine,
or a similar med

Preparatomtale

1.
NAME OF THE MEDICINAL PRODUCT
Citalopram 10 mg Tablets.
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10 mg citalopram, as citalopram hydrobromide.
Excipient(s) with known effect:
Each 10 mg tablet contains 13.3 mg of lactose monohydrate
For the full list of excipients, see 6.1.
3.
PHARMACEUTICAL FORM
Film-coated Tablet.
White, round, flat, bevelled, film-coated tablet.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
Treatment of depressive illness in the initial phase and as
maintenance against potential
relapse/recurrence.
Citalopram is also indicated in the treatment of panic disorder with
or without agoraphobia.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
TREATING DEPRESSION:
_Adults: _
Citalopram should be administered as a single oral dose of 20 mg
daily. Dependent on
individual patient response, the dose may be increased to a maximum of
40 mg daily. In
general, improvement in patients starts after one week, but may only
become evident from
the second week of therapy.
As with all antidepressant medicinal products, dosage should be
reviewed and adjusted, if
necessary, within 3 to 4 weeks of initiation of therapy and thereafter
as judged clinically
appropriate. Although there may be an increased potential for
undesirable effects at higher
doses, if after some weeks on the recommended dose insufficient
response is seen, some
patients may benefit from having their dose increased up to a maximum
of 40 mg a day (see
section 5.1). Dosage adjustments should be made carefully on an
individual patient basis, to
maintain the patient at the lowest effective dose.
A
treatment
period
of
at
least
6
months
is
usually
necessary
to
provide
adequate
maintenance against the potential for relapse.
TREATING PANIC DISORDER:
_Adults: _
In common with other pharmacotherapy used in this patient group, a low
starting dose is
advised to reduce the likelihood of a paradoxical initial anxiogenic
effect.
A single oral dose of 10 mg is recommended for the first week before
increasing the dose to
20 mg daily. Depend